Haleon PLC (H6D0) AI Stock Analysis

Haleon PLC

(XETRA:H6D0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Durable cash generationConsistent operating and free cash flow indicates that Haleon’s earnings are supported by cash rather than accounting effects. This provides capacity to fund brand investment, productivity programs, debt reduction and shareholder distributions through varied market conditions.

Negative Factors

Leverage remains elevatedAlthough debt declined in 2025, leverage remains higher than earlier years, leaving less balance-sheet flexibility than Haleon previously had. This can constrain capital allocation and make the company more sensitive to weaker operating performance or prolonged cost pressure.

Haleon PLC (H6D0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 28.09B
Dividend Yield: 1.39%
Average Volume (3M): 23.64K
Price to Earnings (P/E): 17.6
Beta (1Y): 0.16
Revenue Growth: -2.12%
EPS Growth: 4.80%
Country: Germany
Employees: 24,535
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Haleon PLC Business Overview & Revenue Model

Company Description

Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin Amer...

Haleon PLC Earnings Call Summary

Earnings Call Date:Jul 29, 2026(Q2-2026)|% Change Since:-12.59%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentPositive

The call presented a constructive operational and financial picture: solid organic growth (3.1% in the quarter), strong margin expansion (gross margin +140 bps, operating margin +120 bps) and double‑digit EPS growth, supported by supply‑chain productivity, digital/e‑commerce momentum and targeted regional execution (China, LatAm, India). However, notable near‑term headwinds remain in respiratory/cold & flu, Europe and specific Middle East markets, plus some pricing pressure in APAC from hospital channel activity. Management maintained FY guidance (3%–5%) and expects a stronger second half, suggesting confidence in execution despite the regional and category uncertainties.

Positive Updates

Organic Sales Growth and Volume Improvement

Quarter organic sales growth of 3.1% (up from 2.2% in Q1) with volume/mix at +1.4%; North America delivered 3.1% growth with a 2.0% volume contribution.

Negative Updates

Respiratory Health Weakness

Respiratory category remained weak in Q2 and removed ~150 basis points from organic sales growth; cough & cold (eg, Contac in China) showed little seasonal pickup after two years of category decline, introducing downside risk for Q4 expectations.

Company Guidance

Management reiterated full‑year organic sales guidance of 3–5% (against a medium‑term ambition of 4–6%), saying they expect a stronger H2 with a step‑up in volume mix and broadly similar pricing to H1; Q2 organic was 3.1% (Q1 2.2%) with volume mix 1.4%, North America 3.1% (2% volume) and emerging markets improving to 6.3% (China grew high single‑digit with Douyin >100%). They expect high‑single‑digit operating‑margin growth in H2 and continued operating profit and EPS momentum (H1 EPS +12%), supported by H1 gross margin +140bps, operating margin +120bps (FX +40bps), A&P at 20.9% of sales (A&P +3.2% in H1, 60% digital) and supply‑chain/operating‑model savings of GBP175–200m (roughly one‑third in this year), giving flexibility to absorb Middle‑East cost roll‑offs while increasing H2 investment.

Haleon PLC Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:H6D0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:VLG	71Outperform	GBP 80.73M	15.60	7.82%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:PXS	49Neutral	GBP 18.77M	-80.00	-44.68%	―	-2.14%	0.00%
GB:AGY	42Neutral	GBP 253.30M	-4.04	409.00%	―	2.94%	-32.00%
GB:STX	42Neutral	GBP 60.69M	-7.72	64.57%	―	36.19%	60.75%

* Healthcare Sector Average

Performance Comparison

DE:H6D0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:H6D0	Haleon PLC	3.88	-0.10	-2.54%
GB:AGY	Allergy Therapeutics	4.00	-4.90	-55.06%
GB:PXS	Provexis plc	0.80	0.22	37.93%
GB:STX	Shield Therapeutics	5.65	-1.40	-19.86%
GB:VLG	Venture Life	68.00	14.00	25.93%
GB:BXP	Beximco Pharmaceuticals Limited Sponsored GDR RegS	54.00	12.92	31.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Haleon PLC AI Stock Analysis